Clinical Trial Update: Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating AFQ056 with higher L-dopa doses in Parkinson's disease patients with moderate-severe L-dopa induced dyskinesia; results complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED